Nymox Announces New NX-1207 Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical {NASDAQ: NYMX}  today announced new results from the company’s latest phase 2 trials for it’s NX-1207 prostrate cancer study.

CEO Paul Averback The company were pleased to note the new results demonstrate “the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a significant tangible benefit Continue reading

Inovio selected by DARPA to lead $45 million Ebola Project

Inovio Pharmaceuticals {NASDAQ: INO} has been selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola.

Funding Will Accelerate Development of Inovio’s DNA-Based Monoclonal Antibodies That Could Offer Product Development, Manufacturing, Scale-Up and Dosing Benefits

Continue reading